Skeletal Muscle TRIB3 Mediates Diet-Induced Insulin Resistance

This article originally appeared here.
Share this content:
Skeletal Muscle TRIB3 Mediates Diet-Induced Insulin Resistance
Skeletal Muscle TRIB3 Mediates Diet-Induced Insulin Resistance

WEDNESDAY, May 18, 2016 (HealthDay News) -- Skeletal muscle TRIB3 mediates glucose-induced insulin resistance (GIIR) in a mouse model of diabetes, according to a study published online May 10 in Diabetes.

Wei Zhang, M.D., Ph.D., from the University of Alabama at Birmingham, and colleagues examined whether TRIB3 mediates GIIR in diabetes using muscle-specific TRIB3 overexpressing (MOE) and knockout (MKO) mice.

The researchers found that, compared with wild type mice, TRIB3 MOE exacerbated and MKO prevented GIIR, impaired glucose oxidation, and defects in insulin signal transduction in streptozotocin diabetic mice. Compared with wild type, TRIB3 MOE exhibited greater weight gain and worse insulin resistance in vivo in response to a high-fat diet, coupled with decreased AKT phosphorylation, increased inflammation and oxidative stress, and upregulation of lipid metabolic genes, together with downregulation of glucose metabolic genes in skeletal muscle. In TRIB3 MKO mice, these effects were prevented compared with wild type.

"In conclusion, TRIB3 has both a pathophysiological role in diabetes and a physiological role in metabolism," the authors write. "Under physiological conditions, muscle TRIB3 also influences energy expenditure and substrate metabolism, indicating that the decrease and increase in muscle TRIB3 under fasting and nutrient excess, respectively, are critical for metabolic homeostasis."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »